NasdaqGM:AFMD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has Affimed's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AFMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: AFMD's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

7.1%

AFMD

1.9%

US Biotechs

2.1%

US Market


1 Year Return

105.0%

AFMD

21.2%

US Biotechs

19.8%

US Market

Return vs Industry: AFMD exceeded the US Biotechs industry which returned 21.2% over the past year.

Return vs Market: AFMD exceeded the US Market which returned 19.8% over the past year.


Shareholder returns

AFMDIndustryMarket
7 Day7.1%1.9%2.1%
30 Day65.8%6.5%8.1%
90 Day53.3%7.1%6.0%
1 Year105.0%105.0%23.3%21.2%22.5%19.8%
3 Year167.8%167.8%21.7%15.4%46.5%36.8%
5 Year-27.6%-27.6%14.9%7.0%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is Affimed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Affimed undervalued compared to its fair value and its price relative to the market?

8.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AFMD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AFMD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AFMD is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AFMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AFMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AFMD is overvalued based on its PB Ratio (8.3x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Affimed forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

64.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AFMD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: AFMD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AFMD's is expected to become profitable in the next 3 years.

Revenue vs Market: AFMD's revenue (36.8% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: AFMD's revenue (36.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AFMD's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Affimed performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AFMD is currently unprofitable.

Growing Profit Margin: AFMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AFMD is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.

Accelerating Growth: Unable to compare AFMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AFMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).


Return on Equity

High ROE: AFMD has a negative Return on Equity (-83.98%), as it is currently unprofitable.


Next Steps

Financial Health

How is Affimed's financial position?


Financial Position Analysis

Short Term Liabilities: AFMD's short term assets (€101.4M) exceed its short term liabilities (€45.2M).

Long Term Liabilities: AFMD's short term assets (€101.4M) exceed its long term liabilities (€15.7M).


Debt to Equity History and Analysis

Debt Level: AFMD's debt to equity ratio (2.7%) is considered satisfactory.

Reducing Debt: AFMD's debt to equity ratio has reduced from 8.1% to 2.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AFMD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AFMD has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 8.1% each year.


Next Steps

Dividend

What is Affimed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AFMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AFMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AFMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AFMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AFMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Adi Hoess (58 yo)

9.17yrs

Tenure

€1,316,000

Compensation

Dr. Adi Hoess, M.D., Ph.D., has been the Chief Executive Officer of Affimed N.V. since September 2011 and serves as its Managing Director and Member of Management Board. Dr. Hoess served as Chief Commercia...


CEO Compensation Analysis

Compensation vs Market: Adi's total compensation ($USD1.57M) is about average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Adi's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Adi Hoess
CEO, MD & Member of Management Board9.17yrs€1.32mno data
Wolfgang Fischer
MD, COO & Member of Management Boardno data€872.00k0.45%
€ 2.1m
Melvyn Little
Founder & Consultant20.83yrsno datano data
Angus Smith
Chief Financial Officer0.33yrno datano data
Arndt Schottelius
Chief Scientific Officer0.58yrno datano data
Michael Wolf
Head of Finance & Administration5.83yrsno datano data
Alexander Fudukidis
Head of Investor Relationsno datano datano data
Uwe Reusch
Head of Cell Cultureno datano datano data
Stefan Knackmuss
Head of Antibody Screeningno datano datano data
Sergey Kipriyanov
Head of Research and Developmentno datano datano data
Erich Rajkovic
Head of Research Operations and Intellectual Property4.83yrsno datano data
Claudia Wall
Head of Project Management Regulatory Affairs & Quality Management12.83yrsno datano data

5.8yrs

Average Tenure

53yo

Average Age

Experienced Management: AFMD's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ferdinand Verdonck
Independent Member of Supervisory Board6.33yrs€93.00k0.11%
€ 492.1k
Ulrich Grau
Member of Supervisory Board5.33yrs€93.00k0.096%
€ 440.3k
Miroslav Ravic
Member of Scientific Advisory Boardno datano datano data
Thomas Hecht
Chairman of Supervisory Board6.83yrs€177.00k0.23%
€ 1.1m
Berndt A. Modig
Independent Member of Supervisory Board6.83yrs€81.00k0.11%
€ 492.1k
Susanne Becker
Member of Scientific Advisory Boardno datano datano data
Andreas Engert
Member of Scientific Advisory Boardno datano datano data
Max Topp
Member of Scientific Advisory Boardno datano datano data
Christian Hucke
Member of Scientific Advisory Boardno datano datano data
Anton Hagenbeek
Member of Scientific Advisory Boardno datano datano data
Franck Morschhauser
Member of Scientific Advisory Boardno datano datano data
Ulrike Köhl
Member of Scientific Advisory Boardno datano datano data

6.6yrs

Average Tenure

71yo

Average Age

Experienced Board: AFMD's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.9%.


Top Shareholders

Company Information

Affimed N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Affimed N.V.
  • Ticker: AFMD
  • Exchange: NasdaqGM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$457.529m
  • Shares outstanding: 88.33m
  • Website: https://www.affimed.com

Number of Employees


Location

  • Affimed N.V.
  • Technologiepark
  • Im Neuenheimer Feld 582
  • Heidelberg
  • Baden-Württemberg
  • 69120
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AFMDNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDSep 2014
A28DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2014
0HL9LSE (London Stock Exchange)YesCommon SharesGBUSDSep 2014

Biography

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natu...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 23:07
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.